Updated:
IM Cannabis Corp.
Oren Shuster runs IM Cannabis Corp., a Nasdaq-listed firm operating premium cannabis cultivation and distribution across Israel, Germany, and Canada.
IM Cannabis Corp.
IM Cannabis Corp. was founded in 2019 and is headquartered in Toronto, with key operational hubs in Israel and Germany. The firm was originally established to connect established Israeli medical cannabis genetics and cultivation expertise with the emerging European market, leveraging the experienced Israeli medical cannabis framework. Oren Shuster was named CEO in early 2020 and has led the company through a period of rapid international expansion. The firm's strategy centers on creating a premium, vertically integrated medical cannabis supply chain. It cultivates and processes cannabis in Israel through its subsidiary Focus Medical Herbs Ltd., one of the country's original licensed producers. In Germany, IM Cannabis operates through Adjupharm GmbH, an EU-GMP-certified distributor that imports dried flower from Israel and Canada for distribution to German pharmacies. In Canada, the firm cultivates premium flower under the WAGNERS and Highland Grow brands. The geographic footprint covers three distinct regulatory regimes, allowing the firm to arbitrage supply and demand: exporting Israeli-grown product to Germany, while using Canadian cultivation to supplement volume and brand diversity for European distribution. The company went public on the Canadian Securities Exchange in 2020 and uplisted to the Nasdaq Capital Market in March 2021 (per Reuters, 2021). That same year, it acquired Berlin-based Adjupharm and Canadian licensed producer Trichome Financial Corp. in a reverse takeover that expanded its cultivation capacity in Nova Scotia. In February 2024, IM Cannabis regained compliance with Nasdaq's minimum bid price requirement after executing a 1-for-12 share consolidation (per the firm, February 2024). The firm has no disclosed philanthropic foundation or family office structure. IM Cannabis's structural differentiator is its genuine cross-border Israeli-German-Canadian operational footprint, not merely an export license. By owning cultivation in Israel, a pharmaceutical distribution hub in Germany, and premium cultivation in Canada, the firm sits inside three separate regulatory frameworks simultaneously. This architecture allows it to shift product flows in response to price movements in any single market — a logistical flexibility most European cannabis importers, which operate as single-jurisdiction distributors, cannot replicate.
General information
Firm type
Asset Manager
Year founded
2019
AUM
Undisclosed
Location
Region
North America
Country
Canada
City
Toronto
Corporate office
Toronto, Ontario, Canada
Additional offices
Glil Yam, Israel · Berlin, Germany
Principals
Oren Shuster
Chief Executive Officer
Sector focus
Frequently asked questions
What is IM Cannabis Corp.'s operational structure across its key markets?
The company operates through three main subsidiaries. In Israel, Focus Medical Herbs Ltd. holds one of the country's original cultivation and dispensing licenses. In Germany, Adjupharm GmbH operates as an EU-GMP-certified pharmaceutical wholesaler importing dried flower for German pharmacies. In Canada, Trichome Financial Corp. cultivates premium flower under the WAGNERS and Highland Grow brands. This structure lets the firm export Israeli-grown cannabis to Germany and supplement with Canadian product.
Is IM Cannabis Corp. a single family office or an operating company?
It is an operating company with cultivation, processing, and distribution assets — not a family office or investment vehicle. The firm is publicly traded on the Nasdaq and directly manages production facilities, pharmaceutical import/export logistics, and brand development in its target markets.
How does IM Cannabis Corp.'s cross-border model differ from other European cannabis firms?
Most European cannabis importers are single-jurisdiction distributors that rely on third-party growers. IM Cannabis owns cultivation in both Israel and Canada, plus a pharmaceutical distribution hub in Germany. This operational presence inside three distinct regulatory frameworks gives the firm supply-chain flexibility to redirect product flows in response to price shifts in any single market.
Which regulatory certifications does IM Cannabis Corp. hold in Europe?
Adjupharm GmbH, IM Cannabis's German subsidiary, holds EU-GMP (Good Manufacturing Practice) certification, permitting it to import, repackage, and distribute medical cannabis to German pharmacies. This certification is mandatory for pharmaceutical cannabis products in the European Union.
What cannabis brands does IM Cannabis Corp. cultivate in Canada?
Through its Trichome Financial Corp. subsidiary, the firm cultivates and sells dried flower under the WAGNERS and Highland Grow brands, positioned as premium offerings in the Canadian adult-use and medical markets.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: